Danaher Corporation vs Trip.com Group Ltd — how do they compare? Danaher Corporation trades at $201.9 (market cap $140.88B), while Trip.com Group Ltd trades at $42.99 (market cap $26.95B). The key difference: Danaher Corporation is far larger — about 5.2× Trip.com Group Ltd's market cap, and Danaher Corporation pays the higher dividend (0.8%). Which is the better fit depends on your goals.
| DHR | TCOM | |
|---|---|---|
Market Cap | $140.88B | $26.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $78.96 |
52-Week Low | $161.91 | $39.84 |
Enterprise Value | $153.66B | $19.65B |
Dividend Yield | 0.8% | 0.42% |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
TCOM trades at $42.36, down 1.03% on the day, with a bearish technical signal and recent earnings misses. The stock shows strong fundamentals with a P/E of 6.36, net income margin of 48.65%, and robust cash flow from operations of $19.63 billion in 2024. However, Q1 2026 earnings missed estimates, and Q2 revenue guidance of 3%-8% growth disappointed investors, contributing to recent price weakness.
The outlook is mixed; strong profitability and low valuation offer upside toward the $56.72 consensus price target, but near-term headwinds include regulatory scrutiny and muted guidance. Risks involve antitrust investigations and domestic travel dependency, yet institutional sentiment remains positive with 67% buy ratings.
Trailing returns across standard periods
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →